Latest News and Press Releases

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Company Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis has strengthened its leadership team with CCO and CLO to support its transition to a late-stage company.

In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.

Data at ACR for ESK-001, oral TYK2 inhibitor, demonstrates potential as a high efficacy oral for treatment of Systemic Lupus Erythematosus (SLE).

Alumis reports third quarter 2024 financial results, highlights positive data and near term milestones for its ongoing clinical programs.

Alumis CEO will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Tues Nov 12 at 2:00 pm ET

Late breaking research presentation at EADV shows increasing and sustained responses in 28-week Phase 2 data for ESK-001 in psoriasis

Alumis will be participating in several investor conferences in September

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO...

Alumis announced that patient dosing has commenced in the ONWARD Phase 3 clinical program for ESK-001 for the treatment of psoriasis.